Scarica l'app Stockscreener
166.45
0.28%
-0.46
Pre-mercato:
168.86
2.41
+1.45%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$166.91
Aprire:
$167.01
Volume 24 ore:
2.00M
Relative Volume:
1.80
Capitalizzazione di mercato:
$18.58B
Reddito:
$9.54B
Utile/perdita netta:
$841.00M
Rapporto P/E:
22.37
EPS:
7.44
Flusso di cassa netto:
$1.02B
1 W Prestazione:
-1.14%
1M Prestazione:
-7.23%
6M Prestazione:
+9.04%
1 anno Prestazione:
+14.00%
Intervallo 1D:
$165.30
$167.42
Intervallo di 1 settimana:
$164.65
$170.29
Portata 52W:
$137.71
$182.38
Quest Diagnostics Inc Stock (DGX) Company Profile
Nome
Quest Diagnostics Inc
Settore
Industria
Telefono
(973) 520-2700
Indirizzo
500 PLAZA DRIVE, SECAUCUS
Confronta DGX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
166.45 | 18.80B | 9.54B | 841.00M | 1.02B | 7.44 |
|
TMO
Thermo Fisher Scientific Inc
|
404.94 | 160.56B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
188.07 | 141.52B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
520.87 | 42.74B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
112.04 | 34.11B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
158.96 | 27.70B | 15.50B | 1.33B | 2.16B | 7.34 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-02 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-04 | Downgrade | Citigroup | Buy → Neutral |
| 2025-01-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | Jefferies | Buy |
| 2024-10-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Ripresa | Evercore ISI | In-line |
| 2024-07-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-02-26 | Iniziato | Leerink Partners | Market Perform |
| 2024-02-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-01-03 | Iniziato | Barclays | Equal Weight |
| 2023-12-12 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-06-29 | Iniziato | Piper Sandler | Neutral |
| 2023-05-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-03 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-01-23 | Iniziato | Evercore ISI | In-line |
| 2022-11-17 | Downgrade | Citigroup | Neutral → Sell |
| 2022-08-22 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Downgrade | Citigroup | Buy → Neutral |
| 2022-02-23 | Downgrade | UBS | Buy → Neutral |
| 2022-02-02 | Downgrade | Jefferies | Buy → Hold |
| 2022-01-28 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-03-12 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Aggiornamento | Argus | Hold → Buy |
| 2020-07-29 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-06-09 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-04-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Iniziato | Wells Fargo | Underweight |
| 2020-01-07 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Downgrade | Goldman | Neutral → Sell |
| 2019-04-02 | Aggiornamento | Jefferies | Hold → Buy |
| 2019-03-18 | Ripresa | Credit Suisse | Neutral |
| 2019-01-31 | Downgrade | Argus | Buy → Hold |
| 2019-01-17 | Iniziato | UBS | Neutral |
| 2019-01-03 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Downgrade | Goldman | Buy → Neutral |
Mostra tutto
Quest Diagnostics Inc Borsa (DGX) Ultime notizie
What analysts say about Quest Diagnostics Incorporated stockFree Predictions - Autocar Professional
Quest Diagnostics Earnings Preview: EPS Estimate $2.57, Neutral Consensus Rating, and 12.46% Upside Potential. - AInvest
Should You Buy Quest Diagnostics Ahead of Earnings? - Yahoo Finance
DGX Q2 Earnings Preview: Will Advanced Diagnostics Lead Performance? - Yahoo Finance
Quest Diagnostics Incorporated Stock Analysis and ForecastRecord-setting profit potential - jammulinksnews.com
Quest Diagnostics (DGX) Maintains Neutral Rating Amid Slight PT Adjustment | DGX Stock News - GuruFocus
Quest Diagnostics: UBS Keeps Neutral Rating, Lowers PT to $175 from $176 - AInvest
Quest Diagnostics (DGX) Faces Slight Price Target Adjustment by UBS | DGX Stock News - GuruFocus
What drives Quest Diagnostics Incorporated stock priceHigh-octane investment gains - Jammu Links News
11th Circ. Says Ex-Quest Diagnostics Worker's FCA Suit Fails - Law360
Will Quest Diagnostics (DGX) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Quest Lab Worker Fails to Revive Billing Fraud Suit on Appeal - Bloomberg Law News
Quest to offer Fujirebio’s FDA-cleared Alzheimer’s blood test - MedTech Dive
Quest Diagnostics (DGX) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
Quest Diagnostics launches test for Oropouche virus amid spread in Americas - Investing.com Canada
Quest Diagnostics (DGX) Launches Oropouche Virus Test | DGX Stoc - GuruFocus
Quest Diagnostics Introduces Testing for Oropouche Virus - MarketScreener
First-Ever Commercial Test for Dangerous Oropouche Virus Launches as Disease Spreads in Americas - Stock Titan
Quest Diagnostics: Buy Into Future Patient Demand, Undervalued Price Today (DGX) - Seeking Alpha
Quest Diagnostics launches test for Oropouche virus detection in United States; company's California lab will perform PCR testing for emerging disease starting late July 2025 - Industry Intelligence Inc.
Despite Slump, Options Traders May Be Seeing Something With Quest Diagnostics (DGX) - Barchart.com
Quest Diagnostics (DGX) Develops MCaST Blood Test with MD Anderson Cancer Center - Yahoo Finance
Quest Diagnostics Stock Drops 2.51% Amid Analyst Upgrade - AInvest
Quest Diagnostics Surges to 417th in Trading Volume with 2.25 Billion Shares Traded - AInvest
Quest Diagnostics (DGX) Launches FDA-Approved Alzheimer's Test - GuruFocus
Quest Diagnostics to offer Fujirebio Alzheimer's diagnostic test - Seeking Alpha
Quest Diagnostics Launches Revolutionary FDA-Cleared Blood Test to Detect Early Alzheimer's with 97% Accuracy - Stock Titan
Leerink Partners Adjusts PT on Quest Diagnostics to $192 From $189, Maintains Outperform Rating - MarketScreener
Quest Diagnostics Stock Climbs 27.3% in a Year: What's Fueling It? - Nasdaq
Ex-Dividend Reminder: Edison International, Quest Diagnostics and Cousins Properties - Nasdaq
Zacks Industry Outlook Highlights Quest Diagnostics, Encompass Health, DaVita and The Pennant - TradingView
Quest Diagnostics tops NJ life sciences employer list - NJBIZ
Is Quest Diagnostics Stock a Smart Pick for Your Portfolio Now? - Nasdaq
What to Expect From Quest Diagnostics' Q2 2025 Earnings Report - inkl
What To Expect From Quest Diagnostics' Q2 2025 Earnings Report - Barchart.com
Quest Diagnostics (DGX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock - Yahoo Finance
DGX Stock Up on New Blood Test Development Deal With MD Anderson - MSN
Quest Diagnostics Transforms Healthcare Access: $13M in Grants, 1M Free Tests, and 50 New Diagnostic Services - Stock Titan
Quest Diagnostics to Release Second Quarter 2025 Financial Results on July 22, 2025 – Company Announcement - Financial Times
Is Quest Diagnostics Stock Outperforming the Nasdaq? - MSN
Is Quest Diagnostics Stock Outperforming The Nasdaq? - Barchart.com
Here's How Much You Would Have Made Owning Quest Diagnostics Stock In The Last 5 Years - Benzinga
Quest Diagnostics stock hits all-time high of $180.11 By Investing.com - Investing.com Canada
Quest partners with MD Anderson to develop cancer risk blood test - MedTech Dive
Quest Diagnostics and University of Texas want to promote more cancer screenings - Mugglehead Magazine
Fecal Immunochemical Diagnostic Test (FIT) Market Top - openPR.com
Quest Diagnostics (DGX) Collaborates with MD Anderson for Cancer Risk Test Development | DGX Stock News - GuruFocus
Quest Diagnostics New Blood Test Could Transform Early Cancer Detection for 9 Major Cancers - Stock Titan
Quest Diagnostics Incorporated : The stock forcefully approaches new pivot levels - MarketScreener
Quest Diagnostics (DGX) Stock Analysis: Navigating a 5.5% Upside with Strong Revenue Growth - DirectorsTalk Interviews
Quest Diagnostics Inc Azioni (DGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.25%
0.28%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):